Drugs / Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion
Follow
re-read 2 minutes ago
Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion
targets CD33 via inhibition
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05662904 | Jan 2028 → Jan 2029 expected | acute myeloid leukemia | German Cancer Research Center | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05662904 ↗ |
| Action | Inhibit | “CRISPR/Cas9-mediated inactivation of CD33 in hematopoietic stem cells (HSC)” NCT05662904 ↗ |
| Target | CD33 | “CRISPR/Cas9-mediated inactivation of CD33 in hematopoietic stem cells (HSC)” NCT05662904 ↗ |